(NASDAQ: CING) Cingulate's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.37%.
Cingulate's revenue in 2026 is $0.On average, 7 Wall Street analysts forecast CING's revenue for 2026 to be $22,768,824, with the lowest CING revenue forecast at $0, and the highest CING revenue forecast at $95,238,340. On average, 5 Wall Street analysts forecast CING's revenue for 2027 to be $149,497,449, with the lowest CING revenue forecast at $92,307,930, and the highest CING revenue forecast at $246,642,882.
In 2028, CING is forecast to generate $263,992,772 in revenue, with the lowest revenue forecast at $239,468,028 and the highest revenue forecast at $286,936,026.